Clinical Features, Pathological Findings and Treatment of Recurrent Dermatofibrosarcoma Protuberans

Li, Yanan; Xiang, Bo; Chen, Siyuan; Li, Li; Ji, Yi

doi:10.7150/jca.17988

Cited by 31 publications

(40 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The risk factors for recurrences identified in the current study with multivariate analysis (FS change and R1 resection) are in line with previously published data. 8,10,[12][13][14][15][16][17][18] The median time to recurrence in previous studies ranged from 18.5 to 40.6 months 10,16,[19][20][21] ; whereas, in our study, the median time to recurrence was 55.5 months. This demonstrates that recurrences can occur even many years after the primary tumor, possibly leading to an underestimation of the median time to recurrence in studies with shorter follow-up.…”

Section: Discussioncontrasting

confidence: 70%

Outcome after surgical treatment of dermatofibrosarcoma protuberans: Is clinical follow‐up always indicated?

Veld

Coevorden

Grünhagen

et al. 2019

Cancer

View full text Add to dashboard Cite

BACKGROUND: Dermatofibrosarcoma protuberans (DFSP) is a rare soft tissue sarcoma for which clinical examination up to 10 years is recommended. The objective of this study was to identify prognostic factors for recurrences and metastases that can be used to evaluate the validity of follow-up schedules after treatment for DFSP. METHODS: Patients with DFSP who received treatment between 1991 and 2016 at 3 tertiary centers were included. Cox regression analyses were conducted to identify variables associated with the primary endpoints. RESULTS: In total 357 patients were included, with a median age of 38 years (age range, 2-87 years) and a median follow-up of 60 months (interquartile range, 24-115 months). Eighty-one patients developed recurrent disease (22.7%), and the median time to recurrence was 55.5 months (interquartile range, 20-90 months). Of these, 50 tumors (61.7%) were identified by patient self-examination, whereas 3 recurrences (3.7%) were identified at clinical surveillance. For the remaining 28 tumors, no information was available on how the recurrences were identified (34.6%). Fibrosarcomatous change (hazard ratio, 21.865; P < .001), and positive resection margins (hazard ratio, 14.645; P < .001), were independent prognostic factors for recurrence. Metastases occurred in 4 patients (1.1%). All tumors were identified by imaging after patients presented with symptomatic metastases. Fibrosarcomatous change (P < .001) and tumor size >5 cm (P = .014) were associated with the development of metastases. CONCLUSIONS: Disease recurrence after resection of DFSP remains a significant issue, whereas metastases are uncommon. The majority of recurrences are identified by patient self-examination. Consideration should be given to individualized follow-up schedules based on risk factors for recurrences and metastases. Cancer 2019;125:735-741.

show abstract

Section: Discussioncontrasting

confidence: 70%

Outcome after surgical treatment of dermatofibrosarcoma protuberans: Is clinical follow‐up always indicated?

Veld

Coevorden

Grünhagen

et al. 2019

Cancer

View full text Add to dashboard Cite

show abstract

“…In several studies, however, FS changes were detected only in recurrent tumors [12,41]. Interestingly, our previous study showed that the proportion of FS-DFSP in the recurrent DFSP was higher than the primary DFSP [17]. In a multicenter study, Eva A et al revealed that after WLE, patients with FS-DFSP more often experienced recurrence than those with C-DFSP [14].…”

Section: Discussionmentioning

confidence: 99%

“…The frequency of FS change according to histopathology may be 5% to 15% of DFSP cases, with a high rate of local and distant metastasis [12,13]. It has been suggested that FS change might be a risk factor for local recurrence [14][15][16][17].…”

Section: Introductionmentioning

confidence: 99%

Clinicopathological Features of Fibrosarcomatous Dermatofibrosarcoma Protuberans and the Construction of a Back-Propagation Neural Network Recognition Model

Liang²,

et al. 2020

Preprint

Self Cite

View full text Add to dashboard Cite

BackgroundFibrosarcomatous dermatofibrosarcoma protuberans (FS-DFSP) is a form of tumor progression of dermatofibrosarcoma protuberans (DFSP) with an increased risk of metastasis and recurrence. Few studies have compared the clinicopathological features of FS-DFSP and conventional DFSP (C-DFSP).ObjectivesTo better understand the epidemiological and clinicopathological characteristics of FS-DFSP.MethodsWe conducted a cohort study of 221 patients diagnosed with DFSP and built a recognition model with a back-propagation (BP) neural network for FS-DFSP.ResultsTwenty-six patients with FS-DFSP and 195 patients with C-DFSP were included. There were no differences between FS-DFSP and C-DFSP regarding age at presentation, age at diagnosis, sex, size at diagnosis, size at presentation, and the size interval. The negative ratio of CD34 in FS-DFSP (11.5%) was significantly lower than that in C-DFSP (5.1%) (P=0.005). The average Ki-67 index of FS-DFSP (18.1%) cases was significantly higher than that of C-DFSP (8.1%) cases (P<0.001). The classification accuracy of the BP neural network model training samples was 100%. The correct rates of classification and misdiagnosis were 84.1% and 15.9%.ConclusionsThe clinical manifestations of FS-DFSP and C-DFSP are similar but have large differences in immunohistochemistry. The classification accuracy and feasibility of the BP neural network model are high in FS-DFSP.

show abstract

“…Recently, fibrosarcomatous differentiation has been identified as a risk factor for local recurrence [ 9 ]. The transformation also increases the rate of metastasis (risk ratio 5.5) and death from disease (risk ratio 6.2) [ 10 ].…”

Section: Discussionmentioning

confidence: 99%

Dermatofibrosarcoma Protuberans: Retrospective Single Center Analysis Over 16 Years

Wollina¹,

Langner²,

Schönlebe³

et al. 2018

Open Access Maced J Med Sci

View full text Add to dashboard Cite

Dermatofibrosarcoma protuberans (DFSP) is rare mesenchymal neoplasia with a high risk of local recurrence but a low risk of metastatic spread. Tumor cells express CD34 and show a characteristic translocation t(17;22)(q22;q13). We analysed the documented cases at the Department of Dermatology and Allergology between 08/2001 and 08/2017. The diagnosis had been confirmed by histology and immunohistology in all cases. We identified four adults and a pediatric patient with DFSP. All patients were treated by wide surgical excision and controlled by three-dimensional histologic margin control. We observed no recurrence and no metastatic spread. We discuss prognostic factors and emerging treatments.

show abstract

Clinical Features, Pathological Findings and Treatment of Recurrent Dermatofibrosarcoma Protuberans

Cited by 31 publications

References 23 publications

Outcome after surgical treatment of dermatofibrosarcoma protuberans: Is clinical follow‐up always indicated?

Outcome after surgical treatment of dermatofibrosarcoma protuberans: Is clinical follow‐up always indicated?

Clinicopathological Features of Fibrosarcomatous Dermatofibrosarcoma Protuberans and the Construction of a Back-Propagation Neural Network Recognition Model

Dermatofibrosarcoma Protuberans: Retrospective Single Center Analysis Over 16 Years

Contact Info

Product

Resources

About